Despite in vivo studies suggesting an important role for PPARG in prostate tumour growth and conventional epidemiological studies suggesting a link between pioglitazone use and elevated prostate cancer risk, our combined MR and co-localisation analyses did not find consistent evidence for an association of genetically proxied PPARG perturbation with prostate cancer risk [6, 18]. The gene discussed is PPARG; the disease is prostate cancer.